Autism spectrum disorder (ASD) is a heritable neurodevelopmental disorder with the underlying etiology yet incompletely understood and no cure treatment. Patients of fragile X syndrome (FXS) also manifest symptoms, e.g. deficits in social behaviors, that are core traits with ASD. Several studies demonstrated that a mutual defect in retinoic acid (RA) signaling was observed in FXS and ASD. However, it is still unknown whether RA replenishment could pose a positive effect on autistic-like behaviors in FXS. Herein, we found that RA signaling was indeed down-regulated when the expression of was impaired in SH-SY5Y cells. Furthermore, RA supplementation rescued the atypical social novelty behavior, but failed to alleviate the defects in sociability behavior or hyperactivity, in knock-out (KO) mouse model. The repetitive behavior and motor coordination appeared to be normal. The RNA sequencing results of the prefrontal cortex in KO mice indicated that deregulated expression of and other neuronal genes was restored to normal after RA treatment. Gene ontology terms of metabolic processes, extracellular matrix organization and behavioral pathways were enriched. Our findings provided a potential therapeutic intervention for social novelty defects in FXS.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247356PMC
http://dx.doi.org/10.3389/fgene.2022.928393DOI Listing

Publication Analysis

Top Keywords

retinoic acid
8
social novelty
8
acid supplementation
4
supplementation rescues
4
social
4
rescues social
4
social deficits
4
deficits knockout
4
knockout mice
4
mice autism
4

Similar Publications

Acne and acne sequelae can have an important impact on patients' quality of life, affecting interpersonal relationships and social functioning. Acne-induced scars (AIS) and acne-induced macular hyperpigmentation (AIH), in particular, are a major concern for patients with acne, as their management is challenging and often unsatisfactory. Retinoids are considered the mainstay of acne treatment because of their action on multiple pathogenetic factors, and there is increasing evidence that they can also improve AIS and AIH.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Olabisi Onabanjo University, Sagamu, Ogun, Nigeria.

Background: Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid beta proteins to form plaques and the aggregation of hyperphosphorylated tau to form neurofibrillary tangles. Human fibroblast (SH-SY5Y) cells endogenously express Tau, and the expression is further amplified upon differentiation into neuronal cells, making it a cell model of Alzheimer's disease. Nigella sativa oil (NSO) contains 50% thymoquinone and has been used in the treatment of various nervous system disorders.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Deakin University, Geelong, VIC, Australia.

Background: Reliable treatment approaches for addressing early cognitive impairment and Alzheimer's disease (AD) are currently lacking. Given the multifactorial nature of AD, therapeutic strategies need to focus on disease-specific biochemical pathways. Given the significance of metabolic pathways in cognitive impairment, it is essential to investigate alternative disease modifiers capable of targeting multiple metabolic pathways, such as phytochemicals.

View Article and Find Full Text PDF

Deficiency of Epithelial PIEZO1 Alleviates Liver Steatosis Induced by High-Fat Diet in Mice.

Int J Biol Sci

January 2025

Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

PIEZO1 has been found to play a vital role in regulating intestinal epithelial cells (IEC) function and maintaining intestinal barrier in recent years. Therefore, IEC PIEZO1 might exert a significant impact on liver metabolism through the gut-liver axis, but there is no research on this topic currently. Classic high-fat diet (HFD) model and mice with IEC-specific deficiency of PIEZO1 ( ) were used to explore the problem.

View Article and Find Full Text PDF

Ponatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia and acute lymphoblastic leukemia, can cause rare cutaneous side effects. In this case, a 63-year-old woman developed a pityriasis rubra pilaris-like eruption 1 month after starting the drug. The skin reaction improved with dose reduction and recurred more mildly at a lower dose.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!